Drug Utilization and Quality of Life Study in Coronary Artery Disease

Abstract

Background: Lifestyle modification and optimal pharmacotherapy particularly with newlineevidence-based medications (EBMs) play a key role in the secondary prevention of newlineCardiovascular diseases. newlineMethod: The drug utilization study conducted under this project was a cross sectional, newlinedescriptive, observational study in which prescriptions of 250 Coronary Artery Disease newline(CAD) patients were screened and analyzed. Another study was an open label, randomized, newlineexperimental clinical study conducted in 312 medically managed stable CAD patients to newlineevaluate the effectiveness of a mobile health educational program on the health-related newlinequality of life (HRQOL), Physical activity and body mass index (BMI) of CAD patients. The newlineData collection was done at baseline, 6 and 9 months for both experimental and nonexperimental newlinegroups. newlineResult and conclusion: In drug utilization study results showed areas of improvement and newlinerequirement of more customized individual risk assessment for certain drug classes. Overall newlineprescription of EBMs was found to be rational and appropriate. The m-health based study newlineshowed that there was an improvement in most of the HRQOL parameters from baseline to 6 newlinemonths in both the groups. But the improvement in experimental group was found to be newlinestatistically significantly better (plt0.05) in the experimental group as compared to nonexperimental newlinegroup for baseline to 6 months and also in overall study duration from baseline newlineto 9-month time point. Comparative analysis of physical activity recorded at the three data newlinecollection points showed improvement in experimental group at different time points. For newlineBMI, the comparative statistical analysis showed no significant improvement in either of the newlinegroups. However, there was significant increase in the weight of participants from baseline to newlineFU1 (p=0.04) and overall, from baseline to FU2 (p=0.00) in non-experimental group. newline